维利西胍在心力衰竭伴射血分数降低型患者中的作用

萨日娜 韩(内蒙古医科大学内蒙古临床医学院，中国;)
喜 刘(内蒙古自治区人民医院，中国;)

摘要

心力衰竭（HF）是一种严重影响人群健康的临床综合征，其中伴射血分数降低的心力衰竭（HFrEF）是主要表现。维利西胍作为一种新型可溶性鸟苷酸环化酶（sGC）刺激剂，已被批准用于HFrEF患者的治疗。本研究通过全球临床试验评估维利西胍在HFrEF患者中的疗效，结果显示，在标准药物治疗基础上添加维利西胍显著降低了心血管死亡和HF住院的风险。该研究强调了维利西胍作为HFrEF治疗的新选择，对改善该人群的预后具有重要意义。该综述主要介绍了维利西胍可能的作用机制及其治疗伴射血分数降低心力衰竭的临床研究。

关键词

心力衰竭伴射血分数降低；维利西胍；心血管死亡；住院率

参考

National Healthcare Security Administration. Statistical Bulletin of the Development of National Medical Security in 2019.

Wang L, Duo X, Sun H, ET AL. Cost-utility analysis of add-on verification for the treatment of chronic heart failure with reduced ejection fraction in China[J]. BMC Public Health, 2024, 24(1): 1275.

Trujillo M E, Ayalasomayajula S, Blaustein R O, et al. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2023 December; 16 (12): 2458–66[EB/OL].

Kourek C, Briasoulis A, Papamichail A, et al. Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium[J]. International Journal of Molecular Sciences, 2024, 25(6): 3113.

Stretti L, Zippo D, Coats A J S, et al. A year in heart failure: an update of recent findings[J]. ESC Heart Failure, 2021, 8(6): 4370-4393.

Falco L, Brescia B, Catapano D, et al. Vericiguat: The Fifth Harmony of heart failure with reduced ejection fraction[J]. Journal of Cardiovascular Development and Disease, 2023, 10(9): 388.

Trujillo M E, Ayalasomayajula S, Blaustein R O, et al. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science[J]. Clinical and Translational Science, 2023, 16(12): 2458-2466.

Armstrong P W, Pieske B, Anstrom K J, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. New England Journal of Medicine, 2020, 382(20): 1883-1893.

Khan M S, Xu H, Fonarow G C, et al. Applicability of vericiguat to patients hospitalized for heart failure in the United States[J]. Heart Failure, 2023, 11(2): 211-223.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i3.24752